Nature Communications (Aug 2023)

Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing

  • Sandra Wimberger,
  • Nina Akrap,
  • Mike Firth,
  • Johan Brengdahl,
  • Susanna Engberg,
  • Marie K. Schwinn,
  • Michael R. Slater,
  • Anders Lundin,
  • Pei-Pei Hsieh,
  • Songyuan Li,
  • Silvia Cerboni,
  • Jonathan Sumner,
  • Burcu Bestas,
  • Bastian Schiffthaler,
  • Björn Magnusson,
  • Silvio Di Castro,
  • Preeti Iyer,
  • Mohammad Bohlooly-Y,
  • Thomas Machleidt,
  • Steve Rees,
  • Ola Engkvist,
  • Tyrell Norris,
  • Elaine B. Cadogan,
  • Josep V. Forment,
  • Saša Šviković,
  • Pinar Akcakaya,
  • Amir Taheri-Ghahfarokhi,
  • Marcello Maresca

DOI
https://doi.org/10.1038/s41467-023-40344-4
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 18

Abstract

Read online

Abstract Genome editing, specifically CRISPR/Cas9 technology, has revolutionized biomedical research and offers potential cures for genetic diseases. Despite rapid progress, low efficiency of targeted DNA integration and generation of unintended mutations represent major limitations for genome editing applications caused by the interplay with DNA double-strand break repair pathways. To address this, we conduct a large-scale compound library screen to identify targets for enhancing targeted genome insertions. Our study reveals DNA-dependent protein kinase (DNA-PK) as the most effective target to improve CRISPR/Cas9-mediated insertions, confirming previous findings. We extensively characterize AZD7648, a selective DNA-PK inhibitor, and find it to significantly enhance precise gene editing. We further improve integration efficiency and precision by inhibiting DNA polymerase theta (Polϴ). The combined treatment, named 2iHDR, boosts templated insertions to 80% efficiency with minimal unintended insertions and deletions. Notably, 2iHDR also reduces off-target effects of Cas9, greatly enhancing the fidelity and performance of CRISPR/Cas9 gene editing.